The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis

To the Editor: Quinacrine, a compounded antimalarial, has been used for patients intolerant or unresponsive to hydroxychloroquine. In March 2016, the Pharmacy Compounding Advisory Committee raised safety concerns about quinacrine-associated aplastic anemia. In addition, the Office of New Drugs advised that although quinacrine might be safe at the 100 mg/day dose prescribed for rheumatic skin diseases, generalists might prescribe this drug at higher doses and for alternative indications that have yet to be formally studied.

http://ift.tt/2tijpyG